Literature DB >> 2183709

In vitro emergence of quinolone-resistant mutants of Escherichia coli, Enterobacter cloacae, and Serratia marcescens.

M Watanabe1, Y Kotera, K Yosue, M Inoue, S Mitsuhashi.   

Abstract

Norfloxacin- and ciprofloxacin-resistant mutants of several Enterobacter cloacae and Serratia marcescens isolates occurred at frequencies of greater than or equal to 10(-7)/CFU, which were higher than those of Escherichia coli isolates, in accordance with the increasing emergence of less-susceptible or resistant strains in clinical isolates of E. cloacae and S. marcescens.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2183709      PMCID： PMC171545          DOI： 10.1128/AAC.34.1.173

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

Review 2.  Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.

Authors:  C C Sanders; W E Sanders
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

3.  Endogenous active efflux of norfloxacin in susceptible Escherichia coli.

Authors:  S P Cohen; D C Hooper; J S Wolfson; K S Souza; L M McMurry; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

4.  Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.

Authors:  D C Hooper; J S Wolfson; K S Souza; C Tung; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

5.  Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.

Authors:  K Hirai; H Aoyama; S Suzue; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

6.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

7.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

8.  Role of porin proteins OmpF and OmpC in the permeation of beta-lactams.

Authors:  A Jaffe; Y A Chabbert; O Semonin
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

9.  In vitro and in vivo antibacterial activity of AT-2266.

Authors:  K Kouno; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

10.  Outer membrane permeation of beta-lactam antibiotics in Escherichia coli, Proteus mirabilis, and Enterobacter cloacae.

Authors:  T Sawai; R Hiruma; N Kawana; M Kaneko; F Taniyasu; A Inami
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191
View more
  14 in total

1.  First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandanavia.

Authors:  M Jonsson; M Walder; A Forsgren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

2.  Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.

Authors:  R R Muder; C Brennen; A M Goetz; M M Wagener; J D Rihs
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA.

Authors:  B L Masecar; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

4.  Identification of a Serratia marcescens clinical isolate with multiple quinolone resistance mechanisms from China.

Authors:  Hai-Fei Yang; Jun Cheng; Li-Fen Hu; Ying Ye; Jia-Bin Li
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

Review 5.  [Comparison of the adverse effect profile of different substances such as penicillins, tetracyclines, sulfonamides and quinolones].

Authors:  H Keller
Journal:  Infection       Date:  1991       Impact factor: 3.553

6.  Cloning and nucleotide sequence of the DNA gyrase gyrA gene from Serratia marcescens and characterization of mutations in gyrA of quinolone-resistant clinical isolates.

Authors:  J H Kim; E H Cho; K S Kim; H Y Kim; Y M Kim
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

7.  Resistance to fluoroquinolones in Escherichia coli isolated from poultry.

Authors:  S Bazile-Pham-Khac; Q C Truong; J P Lafont; L Gutmann; X Y Zhou; M Osman; N J Moreau
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

8.  Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.

Authors:  P Heisig; H Schedletzky; H Falkenstein-Paul
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections.

Authors:  C Peña; J M Albareda; R Pallares; M Pujol; F Tubau; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.